Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Study identification

NCT ID

NCT05712200

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Anthos Therapeutics, Inc.

Industry

Enrollment

2,500 participants

Conditions and interventions

Eligibility (public fields only)

Age range

65 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Dec 26, 2022

Primary completion

Dec 29, 2027

Completion

Dec 29, 2027

Last update posted

Jul 12, 2026

2022 – 2027

United States locations

U.S. sites

174

U.S. states

33

U.S. cities

146

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 615 non-U.S. sites.